CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

Argus Research analyst Jasper Hellweg maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) yesterday. The company’s shares ...

Evercore ISI analyst Umer Raffat maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) on January 31. The company’s shares ...

On that note, time to hustle. Best of luck, and do keep in touch. … When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously ...

Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

The Portfolio Selector features the Argus Focus List, a group of 30 "best idea" stocks generated and regularly updated by Argus' analysts and investment policy committee. It also includes the ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2024 ...

GLP-1 drugs like Ozempic and Wegovy revolutionized weight loss, but their high cost keeps them out of reach for most ...

The FDA has approved Eli Lilly’s Emgality (galcanezumab ... unapproved therapies such as Botox and anti-seizure medication. Teva’s CGRP drug Ajovy (fremanezumab) was approved by the FDA ...

A gang of new migraine drugs are nearing approval, and new data is emerging from contenders from Eli Lilly ... Aimovig in May, and Teva’s fremanezumab in June. Lilly expects an FDA decision ...

Multi-billion-dollar merger and acquisition announcements from Johnson & Johnson, Eli Lilly, and GSK may signal renewed ...

Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets for high-quality clinical trials have been recognised as robust and ...